(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 October 2015 (22.10.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/161276 A3

(51) International Patent Classification:
C12N 9/22 (2006.01) *C12N 15/10* (2006.01)
C12N 5/0783 (2010.01) *C12N 15/113* (2010.01)
C12N 15/864 (2006.01) *C12N 15/63* (2006.01)
C12N 15/90 (2006.01)

(21) International Application Number:
PCT/US2015/026504

(22) International Filing Date:
17 April 2015 (17.04.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/981,636 18 April 2014 (18.04.2014) US
62/138,246 25 March 2015 (25.03.2015) US

(71) Applicant: **EDITAS MEDICINE, INC.** [US/US]; 300 Third Street, First Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **WELSTEAD, G. Grant**; 20 Andrew Street, Cambridge, Massachusetts 02139 (US). **FRIEDLAND, Ari E.**; 661 Tremont St., #5, Boston, Massachusetts 02118 (US). **MAEDER, Morgan L.**; 41 Spring Park Ave., Unit 1, Jamaica Plain, Massachusetts 02130 (US). **BUMCROT, David A.**; 30 Leicester Road, Belmont, Massachusetts 02478 (US).

(74) Agents: **LYON, Charles E.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

[Continued on next page]

(54) Title: CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY




FIG. 1A

(57) Abstract: CRISPR/Cas-related composition and methods for treatment of cancer, in particular by using gRNA molecules comprising a targeting domain which is complementary with a target domain from the FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, TRAC or TRBC gene. In some embodiments, gRNAs are used with Cas9 enzymes to cause a cleavage event in said genes within engineered chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells are modified to reduce, decrease or repress expression of said genes using gRNAs and Cas9 enzymes; said modified CAR T-cells are meant for therapeutic uses, especially for cancer.

WO 2015/161276 A3

(88) Date of publication of the international search report:
10 December 2015